The RAS superfamily of small GTPases consists of approximately 50 protein members divided into several subfamilies. Although the Ras subfamily has been the most extensively studied for its role in malignant transformation, there is an increasing interest in characterizing the Rho GTPases due to the role that these proteins play in the control of cell homeostasis. The Rho GTPases are biological molecular """"""""switches"""""""" that control multiple cellular processes such as growth, differentiation, and transformation by cycling between an inactive (GDP-bound) and an active (GTP- bound) state. The Rho guanine nucleotide exchange factors (GEFs) regulate the Rho GTPases. The Rho GTPase cascade, however, is far from being completely resolved and the contributions of particular Rho GEFs or Rho GTPases to human diseases remain undetermined. We have recently identified a novel gene whose sequence predicts it to be a Rho GEF. This gene called Leukemia Associated Rho GEF, or LARG was found fused with a transcription factor in acute leukemia. We hypothesize that LARG has oncogenic activity that is mediated by its putative Rho GEF activity and, in turn, by its ability to activate Rho GTPase pathways. We propose to test this hypothesis by characterizing the functions of LARG and assessing its relevance to leukemogenesis. We have identified three specific aims to achieve these goals. In the first aim we will characterize in vitro LARG as a GEF for Rho GTPases. In the second specific aim we will determine the role of LARG within the Rho GTPase cascade in vivo by generating transgenic Drosophila lines, and we will characterize e x p ression patterns of the LARG murine homolog (Larg) during mouse embryogenesis by in situ hybridization. In the third specific aim, we will assess the relevance of LARG to the pathogenesis of acute leukemia by analyzing the leukemogenic potential of the LARG fusion gene and other LARG mutants in vitro and in vivo by retroviral transfection of murine stem cells. Ultimately, we believe that this K08 proposal will provide important insights into the regulation of cell functions by this novel Rho GEF, and will provide a firm foundation for future independent investigative basic science work by the principal investigator (P.I.).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA090469-05
Application #
6834630
Study Section
Subcommittee G - Education (NCI)
Program Officer
Eckstein, David J
Project Start
2001-05-01
Project End
2006-04-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
5
Fiscal Year
2005
Total Cost
$132,516
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Liu, Shujun; Liu, Zhongfa; Xie, Zhiliang et al. (2008) Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 111:2364-73
Marcucci, Guido; Maharry, Kati; Radmacher, Michael D et al. (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 26:5078-87
Marcucci, Guido; Maharry, Kati; Whitman, Susan P et al. (2007) High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 25:3337-43
Radmacher, Michael D; Marcucci, Guido; Ruppert, Amy S et al. (2006) Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 108:1677-83
Paschka, Peter; Marcucci, Guido; Ruppert, Amy S et al. (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-11
Marcucci, Guido; Baldus, Claudia D; Ruppert, Amy S et al. (2005) Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 23:9234-42
Byrd, John C; Marcucci, Guido; Parthun, Mark R et al. (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105:959-67
Marcucci, Guido; Mrozek, Krzysztof; Ruppert, Amy S et al. (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 23:5705-17
Marcucci, Guido; Mrozek, Krzysztof; Bloomfield, Clara D (2005) Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 12:68-75
Marcucci, Guido; Stock, Wendy; Dai, Guowei et al. (2005) Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 23:3404-11

Showing the most recent 10 out of 19 publications